ArticleTherapeutic innovation & regulatory science2026
Patient Insights into and Satisfaction with Treatment, Management, and Clinical Research of Hereditary Hemochromatosis.
Article in Therapeutic innovation & regulatory science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionHereditary hemochromatosis (HH) is a metabolic disorder characterized by excessive iron absorption, leading to damage of the liver, heart, and pancreas. The patient experience of living with HH has not been extensively described. We therefore aimed to understand the experiences of patients living with HH, including those who are intolerant to currently recommended treatment.
methodsWe consulted eight patients living with HH from North America, Europe, and Oceania, exploring their diagnostic journey and their lives and care management experiences. We also qualitatively assessed patient levels of satisfaction with their current treatment, evaluated their attitudes and views toward clinical research on HH, and identified potential drivers and barriers to clinical trial participation. A thematic approach was used to analyze the data.
resultsPatients were mostly of Northern or Western European ancestry (n = 7) and currently receiving phlebotomy (n = 6). Two patients were receiving iron chelation therapy. Patients ranged in age from their 20s to 70s. The median time since diagnosis was 2 (range 0‒33) years; 2 patients were diagnosed within the past year. Patients expressed varying levels of satisfaction with their treatment, based on experience of side effects (i.e., fainting, extreme fatigue), the emotional toll, needle phobia, treatment logistics, and time burden. Feelings of altruism, connections with the HH community, and the potential for new treatment options were among the motivators to join a clinical trial, while side effects were viewed as the primary barrier.
conclusionThis research provides insights into the patient experience that can inform treatment management and clinical trial design.
Indexed as
Identifiers
41201762What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.